162 related articles for article (PubMed ID: 38189253)
1. Discovery of Novel and Potent Prolyl Hydroxylase Domain-Containing Protein (PHD) Inhibitors for The Treatment of Anemia.
Xu J; Ding X; Fu Y; Meng Q; Wang L; Zhang M; Xu C; Chen S; Aliper A; Ren F; Zhavoronkov A; Ding X
J Med Chem; 2024 Jan; 67(2):1393-1405. PubMed ID: 38189253
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel 2-[(4-hydroxy-6-oxo-2,3-dihydro-1H-pyridine-5-carbonyl)amino]acetic acid derivatives as HIF prolyl hydroxylase inhibitors for treatment of renal anemia.
Hamada M; Takayama T; Shibata T; Hiratate A; Takahashi M; Yashiro M; Takayama N; Okumura-Kitajima L; Koretsune H; Kajiyama H; Naruse T; Kato S; Takano H; Kakinuma H
Bioorg Med Chem Lett; 2018 Jun; 28(10):1725-1730. PubMed ID: 29681433
[TBL] [Abstract][Full Text] [Related]
3. Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor.
Kiriakidis S; Hoer SS; Burrows N; Biddlecome G; Khan MN; Thinnes CC; Schofield CJ; Rogers N; Botto M; Paleolog E; Maxwell PH
Kidney Int; 2017 Oct; 92(4):900-908. PubMed ID: 28506759
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications.
Kim SY; Yang EG
Molecules; 2015 Nov; 20(11):20551-68. PubMed ID: 26610437
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease.
Sakashita M; Tanaka T; Nangaku M
Contrib Nephrol; 2019; 198():112-123. PubMed ID: 30991411
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Characterization of Vadadustat (AKB-6548), an Oral Small Molecule Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, for the Potential Treatment of Renal Anemia.
Zuk A; Si Z; Loi S; Bommegowda S; Hoivik D; Danthi S; Molnar G; Csizmadia V; Rabinowitz M
J Pharmacol Exp Ther; 2022 Oct; 383(1):11-24. PubMed ID: 35926869
[TBL] [Abstract][Full Text] [Related]
7. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics.
Kular D; Macdougall IC
Pediatr Nephrol; 2019 Mar; 34(3):365-378. PubMed ID: 29569190
[TBL] [Abstract][Full Text] [Related]
8. Preferred Conformation-Guided Discovery of Potent and Orally Active HIF Prolyl Hydroxylase 2 Inhibitors for the Treatment of Anemia.
Wu Y; Zhang L; Sun Z; Qiu X; Chen Y; Su K; Yang L; Du Z; Dong Y; Yang F; Li X; Zhang X
J Med Chem; 2023 Jul; 66(13):8545-8563. PubMed ID: 37367818
[TBL] [Abstract][Full Text] [Related]
9. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors
Yang J; Xing J; Zhu X; Xie X; Wang L; Zhang X
Front Endocrinol (Lausanne); 2023; 14():1131516. PubMed ID: 37008953
[TBL] [Abstract][Full Text] [Related]
10. Protein Hydroxylation by Hypoxia-Inducible Factor (HIF) Hydroxylases: Unique or Ubiquitous?
Strowitzki MJ; Cummins EP; Taylor CT
Cells; 2019 Apr; 8(5):. PubMed ID: 31035491
[TBL] [Abstract][Full Text] [Related]
11. Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases.
Joharapurkar AA; Pandya VB; Patel VJ; Desai RC; Jain MR
J Med Chem; 2018 Aug; 61(16):6964-6982. PubMed ID: 29712435
[TBL] [Abstract][Full Text] [Related]
12. Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
Wu Y; Jiang Z; Li Z; Gu J; You Q; Zhang X
J Med Chem; 2018 Jun; 61(12):5332-5349. PubMed ID: 29856623
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a Potent and Orally Bioavailable Hypoxia-Inducible Factor 2α (HIF-2α) Agonist and Its Synergistic Therapy with Prolyl Hydroxylase Inhibitors for the Treatment of Renal Anemia.
Yu Y; Yang F; Yu Q; Liu S; Wu C; Su K; Yang L; Bao X; Li Z; Li X; Zhang X
J Med Chem; 2021 Dec; 64(23):17384-17402. PubMed ID: 34709043
[TBL] [Abstract][Full Text] [Related]
14. [Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor].
Maruno S; Tanaka T; Nangaku M
Rinsho Ketsueki; 2021; 62(5):371-377. PubMed ID: 34108317
[TBL] [Abstract][Full Text] [Related]
15. Structure-Activity Relationship and Crystallographic Studies on 4-Hydroxypyrimidine HIF Prolyl Hydroxylase Domain Inhibitors.
Holt-Martyn JP; Chowdhury R; Tumber A; Yeh TL; Abboud MI; Lippl K; Lohans CT; Langley GW; Figg W; McDonough MA; Pugh CW; Ratcliffe PJ; Schofield CJ
ChemMedChem; 2020 Feb; 15(3):270-273. PubMed ID: 31751494
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
Kurata Y; Tanaka T; Nangaku M
Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):414-422. PubMed ID: 32452915
[TBL] [Abstract][Full Text] [Related]
17. [Hypoxia-inducible factor-prolyl hydroxylase inhibitors: the "alternative" for EPO?].
Rawee P; Eisenga MF
Ned Tijdschr Geneeskd; 2023 Sep; 167():. PubMed ID: 37823872
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
Souza E; Cho KH; Harris ST; Flindt NR; Watt RK; Pai AB
Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
[TBL] [Abstract][Full Text] [Related]
19. Tetrahydropyridin-4-ylpicolinoylglycines as novel and orally active prolyl hydroxylase 2 (PHD2) inhibitors for the treatment of renal anemia.
Su K; Li Z; Zhang L; Fang S; Mao M; Sun Z; Zhang X
Eur J Med Chem; 2022 Aug; 238():114479. PubMed ID: 35675755
[TBL] [Abstract][Full Text] [Related]
20. DMOG, a Prolyl Hydroxylase Inhibitor, Increases Hemoglobin Levels without Exacerbating Hypertension and Renal Injury in Salt-Sensitive Hypertensive Rats.
Kato S; Takahashi T; Miyata N; Roman RJ
J Pharmacol Exp Ther; 2020 Feb; 372(2):166-174. PubMed ID: 31801803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
